Company: MIRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024077
Chunk: 17

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 17
---
psychoactive marijuana
    analog, delivered morphine-comparable pain relief in a validated animal model of inflammatory pain, without inducing local inflammation.

    ●
    On
    July 10, 2025, MIRA announced new preclinical results from SKNY-1, an oral drug candidate for obesity and nicotine addiction currently
    under definitive agreement for acquisition. In a validated behavioral model used to measure Cannabinoid 1 receptor (CB1)-related
    anxiety-like effects, SKNY-1 demonstrated clear reversal of anxiety-related behavior induced by a CB1 activator, distinguishing it
    from earlier CB1-targeting drugs that were discontinued due to unfavorable safety profiles.

    ●
    On
    July 28, 2025, MIRA announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application
    for Ketamir-2, the Company’s novel oral NMDA receptor antagonist for the treatment of neuropathic pain. The clearance enables
    MIRA to initiate U.S.-based clinical trials.

On
July 29, 2025, MIRA announced new preclinical data evaluating the analgesic effects of its topical Ketamir-2 formulation in a validated
rodent model of pain. The study demonstrated that topical Ketamir-2 significantly reduced both acute and inflammatory pain behaviors
in animals, with a rapid onset of action, durable effect, and efficacy comparable to injected morphine across both phases of the pain
model. These findings support continued development of topical Ketamir-2 for localized pain conditions, including diabetic neuropathy,
postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, osteoarthritis, and other forms of inflammatory pain.

ATM
Sale

On July 1, 2025, under the ATM Agreement, the Company sold and issued 17,373
shares of common stock at an average price per share of $1.3121 and received net proceeds of approximately $0.2 million after deducting
commissions and other fees of $570.

On July 3, 2025, MIRA Pharmaceuticals, Inc. (the “Company”),
sold a total of 1,540,741 shares of its common stock, par value $0.001, in block sales to an institutional investor, at an average price
of $1.2981 share (a premium to the prior days close), through its at-the-market equity offering facility (